Skip to main content

ACP’s updated guideline reshapes the treatment landscape for osteoporosis and low bone mass. This concise, physician-focused white paper distills the changes and what they mean for your patients.

What you’ll learn:

  • The big shift: Bisphosphonates as the preferred first-line therapy.
  • Treatment pathways for very high-risk patients.
  • Where denosumab fits — and when not to use it.
  • Clinical pearls from Drs. Kashif Piracha and Katherine Wysham.

Why Oakstone CME?

For 50 years, Oakstone CME has helped physicians stay current with evolving evidence. Our team translates guideline updates into practical insights — so you can apply them with confidence at the point of care.